269 related articles for article (PubMed ID: 20808288)
1. Minimal RB-responsive E1A promoter modification to attain potency, selectivity, and transgene-arming capacity in oncolytic adenoviruses.
Rojas JJ; Guedan S; Searle PF; Martinez-Quintanilla J; Gil-Hoyos R; Alcayaga-Miranda F; Cascallo M; Alemany R
Mol Ther; 2010 Nov; 18(11):1960-71. PubMed ID: 20808288
[TBL] [Abstract][Full Text] [Related]
2. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
3. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.
Cascallo M; Alonso MM; Rojas JJ; Perez-Gimenez A; Fueyo J; Alemany R
Mol Ther; 2007 Sep; 15(9):1607-15. PubMed ID: 17579575
[TBL] [Abstract][Full Text] [Related]
4. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
5. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
[TBL] [Abstract][Full Text] [Related]
6. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
7. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
8. Linked tumor-selective virus replication and transgene expression from E3-containing oncolytic adenoviruses.
Zhu M; Bristol JA; Xie Y; Mina M; Ji H; Forry-Schaudies S; Ennist DL
J Virol; 2005 May; 79(9):5455-65. PubMed ID: 15827160
[TBL] [Abstract][Full Text] [Related]
9. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.
Rojas JJ; Cascallo M; Guedan S; Gros A; Martinez-Quintanilla J; Hemminki A; Alemany R
Gene Ther; 2009 Dec; 16(12):1441-51. PubMed ID: 19710704
[TBL] [Abstract][Full Text] [Related]
10. Modification of the early gene enhancer-promoter improves the oncolytic potency of adenovirus 11.
Wong HH; Jiang G; Gangeswaran R; Wang P; Wang J; Yuan M; Wang H; Bhakta V; Müller H; Lemoine NR; Wang Y
Mol Ther; 2012 Feb; 20(2):306-16. PubMed ID: 22086234
[TBL] [Abstract][Full Text] [Related]
11. The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.
Xiao LL; Wu YM; Qian J; Tan Y; Xie GL; Zhang KJ; Wang YG; Jia XY; Liu XY
Cancer Biol Ther; 2010 Aug; 10(3):242-50. PubMed ID: 20574150
[TBL] [Abstract][Full Text] [Related]
12. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
[TBL] [Abstract][Full Text] [Related]
13. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
14. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication.
Hernandez-Alcoceba R; Pihalja M; Qian D; Clarke MF
Hum Gene Ther; 2002 Sep; 13(14):1737-50. PubMed ID: 12396626
[TBL] [Abstract][Full Text] [Related]
15. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
16. Targeting interferon-alpha increases antitumor efficacy and reduces hepatotoxicity of E1A-mutated spread-enhanced oncolytic adenovirus.
Shashkova EV; Spencer JF; Wold WS; Doronin K
Mol Ther; 2007 Mar; 15(3):598-607. PubMed ID: 17191072
[TBL] [Abstract][Full Text] [Related]
17. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
18. Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells.
Wei F; Wang H; Chen X; Li C; Huang Q
Cancer Biol Ther; 2014 Oct; 15(10):1358-66. PubMed ID: 25019940
[TBL] [Abstract][Full Text] [Related]
19. Control of E1A under an E2F-1 promoter insulated with the myotonic dystrophy locus insulator reduces the toxicity of oncolytic adenovirus Ad-Delta24RGD.
Majem M; Cascallo M; Bayo-Puxan N; Mesia R; Germa JR; Alemany R
Cancer Gene Ther; 2006 Jul; 13(7):696-705. PubMed ID: 16498429
[TBL] [Abstract][Full Text] [Related]
20. Potent antitumor effect of interleukin-24 gene in the survivin promoter and retinoblastoma double-regulated oncolytic adenovirus.
Zhang KJ; Wang YG; Cao X; Zhong SY; Wei RC; Wu YM; Yue XT; Li GC; Liu XY
Hum Gene Ther; 2009 Aug; 20(8):818-30. PubMed ID: 19320563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
